Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature

Ryobu Mori; Daichi Fujimoto; Munehiro Ito; Keisuke Tomii

doi:10.18632/oncotarget.17952

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature

Ryobu Mori, Daichi Fujimoto _, Munehiro Ito and Keisuke Tomii

PDF | HTML | How to cite

Oncotarget. 2017; 8:48521-48524. https://doi.org/10.18632/oncotarget.17952

Metrics: PDF 2532 views | HTML 2847 views | ?

Abstract

Ryobu Mori1, Daichi Fujimoto1, Munehiro Ito1 and Keisuke Tomii1

1 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan

Correspondence to:

Daichi Fujimoto, email:

Keywords: bevacizumab, malignant pleural effusion, non-small cell lung cancer, ramucirumab, vascular endothelial growth factor

Received: February 14, 2017 Accepted: May 01, 2017 Published: May 17, 2017

Abstract

Malignant pleural effusion (MPE) is a major problem associated with advanced non-small cell lung cancer for which an optimum treatment strategy has yet to be determined. Notably, vascular endothelial growth factor (VEGF) signaling has been found to influence MPE, and bevacizumab, a VEGF ligand inhibitor, can effectively control MPE. Ramucirumab, a human monoclonal antibody specific for VEGF receptor-2, has recently been approved for advanced non-small cell lung cancer. However, it remains unclear which of these agents more effectively control MPE.

We describe a case of a 68-year-old man with advanced non-small cell lung cancer in whom ramucirumab plus docetaxel-refractory MPE was responsive to bevacizumab plus docetaxel combination therapy. The patient’s MPE progressed after two cycles of ramucirumab plus docetaxel second-line chemotherapy. After switching to bevacizumab plus docetaxel, a computed tomography scan revealed a decreased MPE after two cycles of treatment.

Bevacizumab may be more effective for treating MPE. However, further investigations are still warranted to determine the optimal VEGF-targeted agent for this condition.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17952

Publication Alerts

Oncoscience

Post-Publication Promotion

Case Reports:

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature

Abstract